Auxilium Pharmaceuticals Inc.
40 Valley Stream Parkway
Malvern,
PA 19355
United States - Map
Phone: 484-321-5900
Fax: 484-321-5999
Web Site: http://www.auxilium.com
| Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and select primary care physicians primarily in the United States. It markets Testim, a topical 1% testosterone gel, for the treatment of hypogonadism. The company’s product pipeline includes XIAFLEX, an injectable collagenase enzyme, which is in Phase III of development for the treatment of Dupuytren’s contracture; and in Phase II of development for the treatment of Peyronie’s Disease and Frozen Shoulder Syndrome. Its product pipeline also comprises AA4010, which is in Phase I of development for the treatment of overactive bladder using its transmucosal film delivery system. In addition, the company is developing one pain product, which is in preclinical stage using its transmucosal film delivery system. Further, it has rights to seven additional pain products, and products for hormone replacement and urologic disease using its transmucosal film delivery system, and options to indications using AA4500 for non-topical formulations. The company was founded in 1999 and is headquartered in Malvern, Pennsylvania. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Armando Anido , 50
Chief Exec. Officer, Pres |
$
737.00K | N/A | Mr. James E. Fickenscher , 44
Chief Financial Officer and Principal Accounting Officer |
N/A
| N/A | Ms. Jennifer Evans Stacey Esq., 43
Exec. VP, Gen. Counsel of HR and Sec. |
N/A
| N/A | Mr. Roger D. Graham Jr., 44
Exec. VP of Sales & Marketing |
$
377.00K | N/A | Dr. Jyrki Mattila M.D., Ph.D., 52
Exec. VP of Bus. Devel., Product Devel. & Technical Operations
|
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.32% Nasdaq 
Profile
